Literature DB >> 15816463

Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer.

Takayuki Tohma1, Shinichi Okazumi, Harufumi Makino, Akihiro Cho, Ryoyu Mochiduki, Kiyohiko Shuto, Hidehiro Kudo, Katsuhiko Matsubara, Hisashi Gunji, Takenori Ochiai.   

Abstract

BACKGROUND/AIMS: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been established as a powerful diagnosing modality in clinical oncology. FDG accumulation has been demonstrated to correlate with hexokinase activity. However, recent reports suggest that glucose transporters participate in FDG accumulation. The aim of this study is to evaluate glucose transporter and hexokinase expression and clarify the relationship between them and FDG accumulation.
METHODOLOGY: FDG-PET was performed in 72 preoperative patients with esophageal cancer. The ratios of tumor radioactivity to plasma radioactivity (Ci/Cp values) were obtained 60 minutes after administration. We studied the expressions of glucose transporter 1 (Glut1) and type-II hexokinase (HK-II) by immunohistochemical analysis of the resected specimen. The percentages of cells expressing Glut1 and HK-II were scored on a 5-point scale (1=0-20%, 2=20-40%, 3=40-60%, 4=60-80%, 5=80-100%). Then the 3 scores obtained from 3 counting trials were averaged to give the Glut-index and HK-index.
RESULTS: All esophageal cancers showed marked FDG accumulation. All 72 cancers expressed Glut1 and 71 of 72 cancers expressed HK-II. The Glut-index had a weak correlation with the Ci/Cp value (not significant). The HK-index had a close positive correlation with the Ci/Cp value (p<0.005).
CONCLUSIONS: FDG accumulation correlates more with type-II hexokinase expression than with glucose transporter 1 expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816463

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  22 in total

1.  Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Atsushi Tani; Yoriko Kajiya; Shunji Shimaoka; Akio Matsuda; Tatsuyuki Nioh; Tohru Nihara; Toyokuni Suenaga; Sadao Tanaka; Hiroshi Shirahama; Michiyo Higashi; Chihaya Koriyama
Journal:  Eur Radiol       Date:  2011-07-13       Impact factor: 5.315

2.  Improved surgical results in thoracic esophageal squamous cell carcinoma: a 40-year analysis of 792 patients.

Authors:  Hideaki Shimada; Hisahiro Matsubara; Shinichi Okazumi; Kaichi Isono; Takenori Ochiai
Journal:  J Gastrointest Surg       Date:  2007-09-01       Impact factor: 3.452

Review 3.  In vivo imaging of molecular targets and their function in endocrinology.

Authors:  Joanna E Burdette
Journal:  J Mol Endocrinol       Date:  2008-06       Impact factor: 5.098

4.  2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer.

Authors:  Hossein Jadvar; Robert W Henderson; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2006 May-Jun       Impact factor: 3.488

5.  Oncogene pathway activation in mammary tumors dictates FDG-PET uptake.

Authors:  James V Alvarez; George K Belka; Tien-Chi Pan; Chien-Chung Chen; Eric Blankemeyer; Abass Alavi; Joel S Karp; Lewis A Chodosh
Journal:  Cancer Res       Date:  2014-09-19       Impact factor: 12.701

Review 6.  Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.

Authors:  Elizabeth C Smyth; Manish A Shah
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

7.  Comparison of FDG-PET/CT and MR with diffusion-weighted imaging for assessing peritoneal carcinomatosis from gastrointestinal malignancy.

Authors:  Michael Soussan; Gaëtan Des Guetz; Vincent Barrau; Vanessa Aflalo-Hazan; Gabriel Pop; Ziad Mehanna; Edmond Rust; Thomas Aparicio; Richard Douard; Robert Benamouzig; Philippe Wind; Véronique Eder
Journal:  Eur Radiol       Date:  2012-02-24       Impact factor: 5.315

8.  18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome.

Authors:  Marinke Westerterp; Gerrit W Sloof; Otto S Hoekstra; Fiebo J W Ten Kate; Gerrit A Meijer; Johannes B Reitsma; Ronald Boellaard; J Jan B van Lanschot; Carla F M Molthoff
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-25       Impact factor: 4.553

9.  RRAD inhibits aerobic glycolysis, invasion, and migration and is associated with poor prognosis in hepatocellular carcinoma.

Authors:  Runze Shang; Jianlin Wang; Wei Sun; Bin Dai; Bai Ruan; Zhuochao Zhang; Xisheng Yang; Yuan Gao; Shibin Qu; Xing Lv; Kaishan Tao; Lin Wang; Kefeng Dou; Desheng Wang
Journal:  Tumour Biol       Date:  2015-11-06

10.  Correlation Between 18F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions.

Authors:  Young-Sil An; Se-Hyuk Kim; Tae Hoon Roh; So Hyun Park; Tae-Gyu Kim; Jang-Hee Kim
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.